We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.25%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.05B
AUM Growth
+$53.4M
Cap. Flow
-$44.1M
Cap. Flow %
-4.2%
Top 10 Hldgs %
70.43%
Holding
48
New
17
Increased
6
Reduced
6
Closed
15

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$50.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$35M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$25.1M
4
UBX
Unity Biotechnology
UBX
+$24.6M
5
KZR
Kezar Life Sciences
KZR
+$22.2M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$49.8M
2
WVE icon
Wave Life Sciences
WVE
+$45M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$23.4M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.08%
2 Miscellaneous 12.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
26
CALL
Assembly Biosciences
ASMB
$694M
$5.81M 0.55%
+12,342
New +$6.53M
DBVT
27
DBV Technologies
DBVT
$851M
$5.75M 0.55%
29,810
-15,190
-34% -$3.42M
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.19B
$4.95M 0.47%
450,400
-19,300
-4% -$215K
NGNE icon
29
Neurogene
NGNE
$732M
$3.05M 0.29%
+57,500
New +$15M
TRAW icon
30
Traws Pharma
TRAW
$9.07M
$3.03M 0.29%
+1,333
New +$3.87M
PHXM
31
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$1.73M 0.17%
+15,396
New +$2.89M
APTX
32
DELISTED
Aptinyx Inc. Common Stock
APTX
$992K 0.09%
+41,037
New +$878K
INFI
33
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$787K 0.07%
+412,000
New +$832K
AGIO icon
34
Agios Pharmaceuticals
AGIO
$1.99B
– –
-172,952
Closed -$14.1M
AKBA icon
35
Akebia Therapeutics
AKBA
$243M
– –
-1,425,000
Closed -$13.6M
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,056,348
Closed -$23.4M
DNLI icon
37
Denali Therapeutics
DNLI
$3.84B
– –
-325,000
Closed -$6.4M
GERN icon
38
Geron
GERN
$970M
– –
-350,000
Closed -$1.49M
PTGX icon
39
Protagonist Therapeutics
PTGX
$9.34B
– –
-1,083,567
Closed -$9.31M
RYTM icon
40
Rhythm Pharmaceuticals
RYTM
$7.38B
– –
-318,564
Closed -$6.34M
SYBX
41
DELISTED
Synlogic
SYBX
– –
-46,667
Closed -$6.57M
URGN icon
42
UroGen Pharma
URGN
$2.13B
– –
-402,300
Closed -$20M
ATYR
43
aTyr Pharma
ATYR
$53M
– –
-279,855
Closed -$10.6M
LUMO
44
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-62,222
Closed -$4.06M
KIN
45
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-248,680
Closed -$2.15M
FPRX
46
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-1,240,470
Closed -$21.3M
DOVA
47
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
– –
-429,729
Closed -$11.7M
ARRY
48
DELISTED
Array Biopharma Inc
ARRY
– –
-3,049,312
Closed -$49.8M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2018 Portfolio in Review

As of Q2 2018, EcoR1 Capital held 48 positions worth $1.05B, up 5.4% from $997M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

EcoR1 Capital withdrew a net $44.1M in Q2 2018, closing 15 positions and reducing 6 holdings. Its most notable exit was Array Biopharma Inc, an estimated $49.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Scholar Rock worth $41.7M.

  • EcoR1 Capital's largest Q2 2018 buy was Scholar Rock: 2,671,161 shares worth $41.7M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q2 2018, an estimated $6.44M increase.
  • EcoR1 Capital's biggest Q2 2018 reduction was Wave Life Sciences, cutting an estimated $45M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q2 2018, selling an estimated $49.8M.
  • EcoR1 Capital's ten largest holdings make up 70% of its $1.05B portfolio in Q2 2018.
  • EcoR1 Capital opened 17 new positions and closed 15 in Q2 2018.
  • EcoR1 Capital's portfolio value rose 5.4% quarter-over-quarter to $1.05B.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.